Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Ebola virus
- Ebola virus GP (glycoprotein)
- GP structure
- GP crystallization
- Final crystallization construct
- Physiological relevance
- Final crystals
- GP crystal structure
- GP structure (360 view)
- GP trimer interface
- How is GP assembled?
- GP1 and GP2 subdomains
- GP1 base domain (1)
- GP1 base domain (2)
- GP1 head domain
- GP1 glycan cap
- GP2 N terminus
- GP2 internal fusion loop
- GP2 heptad repeat 1
- Three HR1D subunits form the trimer interface
- Three internal fusion loops wrap around the trimer
- GP function in attachment, fusion and entry
- GP residues important for attachment
- Putative receptor binding sites
- Glycan caps
- Biantennary glycans
- Mucin-like domain make GP 5-12 times bigger
- When and how does the RBS come into play?
- How is the RBS exposed?
- Probable cathepsin cleavage site
- After cleavage with cathepsin
- Hypothesis for entry
- Model for entry
- What is left exposed for immune surveillance?
- Survivor Fab KZ52 neutralizes in vitro
- Three KZ52 Fabs bound to GP trimer
- KZ52 is primarily an anti-GP2 antibody
- Effect of KZ52
- KZ52 bridges N term of GP2, IFL of GP2, and GP1
- GP amino acids interacting with KZ52
- Sudan ebolavirus (1)
- Sudan ebolavirus (2)
- Crystals of Sudan ebolavirus GP
- Sudan ebolavirus GP bound to the 16F6 mAb
- KZ52 and 16F6 binding sites overlap
- How might Abs against the shared site neutralize?
- What are those conformational changes?
- Prefusion and postfusion GPs
- Possible conformational changes at fusion (1)
- Possible conformational changes at fusion (2)
- Thanks
Topics Covered
- Structure of Zaire ebolavirus GP Receptor binding
- Cathepsin cleavage
- Immune evasion Structure of Sudan ebolavirus GP
- GP epitopes of two neutralizing antibodies
- Proposed conformational changes in fusion
Links
Categories:
Therapeutic Areas:
Talk Citation
Ollmann Saphire, E. (2011, March 30). A shared structural solution for neutralizing ebolaviruses [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/TEGG2723.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Erica Ollmann Saphire has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.